(Q28292014)

https://api.crossref.org/works/10.1007/S00280-010-1434-6

3 July 2024

1 reference

5

Everardo Cobos

0 references

author name string

Changxia Shao

1

0 references

Chuanwen Lu

2

0 references

Lixia Chen

3

0 references

Weimin Gao

6

0 references

Patrick P. Koty

4

1 reference

Europe PubMed Central

PubMed publication ID

20803015

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20803015

3 July 2024

language of work or name

English

0 references

publication date

June 2011

0 references

28 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

20803015

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20803015

full work available at URL

3 July 2024

http://link.springer.com/content/pdf/10.1007/s00280-010-1434-6.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1007/S00280-010-1434-6

http://link.springer.com/article/10.1007/s00280-010-1434-6/fulltext.html

3 July 2024

1 reference

https://api.crossref.org/works/10.1007/S00280-010-1434-6

http://link.springer.com/content/pdf/10.1007/s00280-010-1434-6

3 July 2024

1 reference

https://api.crossref.org/works/10.1007/S00280-010-1434-6

Cancer Chemotherapy and Pharmacology

3 July 2024

published in

0 references

volume

67

0 references

issue

6

0 references

page(s)

1369-80

0 references

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Carcinogenicity studies of inhaled cigarette smoke in laboratory animals: old and new.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

p53, the cellular gatekeeper for growth and division

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Comparison of p53 mutations between adenocarcinoma and squamous cell carcinoma of the lung: unique spectra involving G to A transitions and G to T transversions in both histologic types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Regulation of p53 tetramerization and nuclear export by ARC

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Nucleocytoplasmic transport: taking an inventory

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Identification of nuclear export inhibitors with potent anticancer activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Nuclear transport and cancer: from mechanism to intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Effects of leptomycin B on the cell cycle of fibroblasts and fission yeast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Transport into and out of the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Structural biology of nucleocytoplasmic transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Combined effects of p53 gene therapy and leptomycin B in human esophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Leptomycin B stabilizes and activates p53 in primary prostatic epithelial cells and induces apoptosis in the LNCaP cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

p53 is required for radiation-induced apoptosis in mouse thymocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Thymocyte apoptosis induced by p53-dependent and independent pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Wild-type p53 is a cell cycle checkpoint determinant following irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Gene expression profiling analysis reveals arsenic-induced cell cycle arrest and apoptosis in p53-proficient and p53-deficient cells through differential gene pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Reliable transcript quantification by real-time reverse transcriptase-polymerase chain reaction in primary neuroblastoma using normalization to averaged expression levels of the control genes HPRT1 and SDHA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Validating nutrient-related gene expression changes from microarrays using RT(2) PCR-arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Elevated expression of protein regulator of cytokinesis 1, involved in the growth of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

DNA damage-induced down-regulation of human Cdc25C and Cdc2 is mediated by cooperation between p53 and maintenance DNA (cytosine-5) methyltransferase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Nuclear export is essential for the tumor-promoting activity of survivin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

MDM2 chaperones the p53 tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

21 January 2018

p53: puzzle and paradigm

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Ubiquitin-dependent degradation of p53 protein despite phosphorylation at its N terminus by acetaminophen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Nuclear export inhibitor leptomycin B induces the appearance of novel forms of human Mdm2 protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

DNA methyltransferase inhibition induces the transcription of the tumor suppressor p21(WAF1/CIP1/sdi1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

p21(WAF1) negatively regulates DNMT1 expression in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

p53 strikes mTORC1 by employing sestrins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Role and prognostic significance of tumor necrosis factor‐related apoptosis‐inducing ligand death receptor DR5 in nonsmall‐cell lung cancer and precursor lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Leptomycin B-induced apoptosis is mediated through caspase activation and down-regulation of Mcl-1 and XIAP expression, but not through the generation of ROS in U937 leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Nuclear export of the yeast hexokinase 2 protein requires the Xpo1 (Crm1)-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

IL-6, but not IFN-gamma, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Inverse effects of interleukin-6 on apoptosis of fibroblasts from pulmonary fibrosis and normal lungs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1434-6

Antitumor activity of leptomycin B

21 January 2018

19

1 reference

https://api.crossref.org/works/10.1007/S00280-010-1434-6

Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis

3 July 2024

37

1 reference

https://api.crossref.org/works/10.1007/S00280-010-1434-6

Proliferation of human non-small-cell lung cancer cell lines: role of interleukin-6

3 July 2024

64

1 reference

https://api.crossref.org/works/10.1007/S00280-010-1434-6

3 July 2024

Identifiers